Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 11Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 8Advanced Solid Tumor 6Squamous Cell Carcinoma of Head and Neck 5Neoplasms 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Solid Tumor 3Small Cell Lung Carcinoma 3Recurrence 3Rectal Neoplasms 3Turcot syndrome 2Sarcoma 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Microsatellite Stable Metastatic Colorectal Cancer 2Locally Advanced Rectal Cancer 2Liposarcoma 2Laryngeal Neoplasms 2Gestational Trophoblastic Disease 2Esophageal Neoplasms 2

Interventions

Injections 3toripalimab 1aflutinib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Lung Cancer × toripalimab × Clear all
NCT07309276 2026-05-18

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
864 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡